Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease
By P. Calverley, W. Boonsawat, Z. Cseke, N. Zhong, S. Peterson, H. Olsson. European Respiratory Journal, 2003
771 citations recorded by the source corpus.
Subfields: Physiology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/bf27a9a2d3c4911d5ebd22ab0b6b6ac999c02af8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Physiology
In Pulmonary and Respiratory Medicine
- J. Wedzicha
- P. Barnes
- T. Seemungal
- A. Anzueto
- P. Calverley
- R. Rodríguez-Roisín
- C. Jenkins
- Sonia Buist
Citations in the corpus
- The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. (2008, methodology): “Patients entered a 2-week run-in period during which they discontinued all existing COPD maintenance medications and received oral prednisolone 30 mg/day and inhaled salmeterol 50 mg twice daily to standardize their clinical condition before randomization, an approach described previously in COPD st”
- COPD exacerbations: defining their cause and prevention (2007, neutral): “98, 99 All of the major recent studies of combination therapy 75, 93, 96, 97 have reported that the combination of inhaled steroid and LABA is more eff ective than either individual drug alone in reducing exacerbation frequency.”
- Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution (2023, neutral): “В ка! честве первой линии терапии рекомендуется комбина! ция ингаляционных ГКС/длительнодействующих β2!аго! нистов или длительнодействующих антихолинергических препаратов [195, 212, 214, 240, 244, 251, 388].”
- Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. (2007, background): “An inhaled glucocorticosteroid combined with a long-acting b2-agonist is more effective than the individual components (123, 125, 126, 130, 131) (Evidence A).”